Limits...
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.

Kaku Y, Nagaya H, Tsuchiya A, Kanno T, Gotoh A, Tanaka A, Shimizu T, Nakao S, Tabata C, Nakano T, Nishizaki T - Cancer Sci. (2014)

Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.

View Article: PubMed Central - PubMed

Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Show MeSH

Related in: MedlinePlus

Cell cycle analysis of NCI-H2052 (a, b) and MSTO-211H cells (c, d) not treated (Control) or treated with HUHS1015 (10 μM) or paclitaxel (10 μM) for 24 h. Typical profiles are shown in upper columns. In the graphs, each column represents the mean (±SEM) percentage for each phase of cell cycling (n = 4 independent experiments). P-values, unpaired t-test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317914&req=5

fig03: Cell cycle analysis of NCI-H2052 (a, b) and MSTO-211H cells (c, d) not treated (Control) or treated with HUHS1015 (10 μM) or paclitaxel (10 μM) for 24 h. Typical profiles are shown in upper columns. In the graphs, each column represents the mean (±SEM) percentage for each phase of cell cycling (n = 4 independent experiments). P-values, unpaired t-test.

Mentions: In the cell cycle analysis by flow cytometry, HUHS1015 increases the proportion of sub-G1 phase NCI-H2052 and MSTO-211H cells (Fig. 3a,c), indicating that HUHS1015 induces apoptosis of these cell lines. HUHS1015 (10 μM) increased the proportion of the G1 and S phases of cell cycling and decreased that of the G2/M phase in NCI-H2052 cells (Fig. 3a). The drug also decreased the proportion of the G1 phase without affecting that of the S and G2/M phases in MSTO-211H cells (Fig. 3c). This suggests no common effect of HUHS1015 on cell cycling among malignant pleural mesothelioma cells.


Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.

Kaku Y, Nagaya H, Tsuchiya A, Kanno T, Gotoh A, Tanaka A, Shimizu T, Nakao S, Tabata C, Nakano T, Nishizaki T - Cancer Sci. (2014)

Cell cycle analysis of NCI-H2052 (a, b) and MSTO-211H cells (c, d) not treated (Control) or treated with HUHS1015 (10 μM) or paclitaxel (10 μM) for 24 h. Typical profiles are shown in upper columns. In the graphs, each column represents the mean (±SEM) percentage for each phase of cell cycling (n = 4 independent experiments). P-values, unpaired t-test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317914&req=5

fig03: Cell cycle analysis of NCI-H2052 (a, b) and MSTO-211H cells (c, d) not treated (Control) or treated with HUHS1015 (10 μM) or paclitaxel (10 μM) for 24 h. Typical profiles are shown in upper columns. In the graphs, each column represents the mean (±SEM) percentage for each phase of cell cycling (n = 4 independent experiments). P-values, unpaired t-test.
Mentions: In the cell cycle analysis by flow cytometry, HUHS1015 increases the proportion of sub-G1 phase NCI-H2052 and MSTO-211H cells (Fig. 3a,c), indicating that HUHS1015 induces apoptosis of these cell lines. HUHS1015 (10 μM) increased the proportion of the G1 and S phases of cell cycling and decreased that of the G2/M phase in NCI-H2052 cells (Fig. 3a). The drug also decreased the proportion of the G1 phase without affecting that of the S and G2/M phases in MSTO-211H cells (Fig. 3c). This suggests no common effect of HUHS1015 on cell cycling among malignant pleural mesothelioma cells.

Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.

View Article: PubMed Central - PubMed

Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Show MeSH
Related in: MedlinePlus